TEVA Q1 2018 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q1 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$5.1B-10.0% YoY

Gross Profit

$2.3B46.4% margin

Operating Income

$1.5B30.1% margin

Net Income

$1.1B20.8% margin

EPS (Diluted)

$1.03

QoQ Revenue Growth

-7.2%

Cash Flow

Operating Cash Flow

$1.5B

Free Cash Flow

$1.3B

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$69.2B

Total Liabilities

$49.1B

Stockholders' Equity

$18.6B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.1B	$5.6B	-10.0%
Gross Profit	$2.3B	$2.8B	-16.7%
Operating Income	$1.5B	$895M	+70.4%
Net Income	$1.1B	$580M	+81.9%

Revenue Segments

Growth Market

$519M75%

Other Activities

$177M25%

Geographic Segments

North America

$2.2B60%

Europe

$1.4B40%